Oncocyte (NASDAQ:IMDX) Raised to “Hold” at Wall Street Zen

Oncocyte (NASDAQ:IMDX) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other analysts also recently issued reports on IMDX. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncocyte in a research note on Wednesday, June 24th. Needham & Company LLC restated a “buy” rating and issued a $9.00 price target on shares of Oncocyte in a research note on Tuesday, August 18th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $10.50.

Oncocyte Stock Performance

Shares of Oncocyte stock opened at $4.00 on Friday. The company has a market capitalization of $130.88 million, a P/E ratio of -2.68 and a beta of 1.80. The company has a fifty day moving average of $4.41 and a 200 day moving average of $4.72. Oncocyte has a fifty-two week low of $2.42 and a fifty-two week high of $8.51.

Oncocyte (NASDAQ:IMDX) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $0.24 million during the quarter.

About Oncocyte

Oncocyte Corporation is a molecular diagnostics company focused on developing and commercializing tests intended to support cancer treatment decisions. Its technologies use genomic and other molecular information to help physicians assess disease characteristics, recurrence risk, and potential response to therapy.

The company’s historical product portfolio has included DetermaRx, a genomic test designed to identify patients with early-stage lung cancer who may face a higher risk of recurrence after surgery, and DetermaIO, which was developed to help evaluate the tumor immune environment and potential response to immunotherapy.